Nichols B, Jog P, Lee JH, et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int. 2015;87(2):332-42. doi:10.1038/ki.2014.270
Wang S, Tsun ZY, Wolfson RL, et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science. 2015;347(6218):188-94. doi:10.1126/science.1257132
Cancer Genome Atlas Research Network, Brat DJ, Verhaak RGW, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015;372(26):2481-98. doi:10.1056/NEJMoa1402121
Chou DHC, Vetere A, Choudhary A, et al. Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling. J Am Chem Soc. 2015;137(24):7929-34. doi:10.1021/jacs.5b04284
Yaffe MB, Gough NR. Leveraging signaling research to understand and treat disease. Sci Signal. 2016;9(421):eg4. doi:10.1126/scisignal.aaf6275
Sweeney C, Fambrough D, Huard C, et al. Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J Biol Chem. 2001;276(25):22685-98. doi:10.1074/jbc.M100602200
Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108-12. doi:10.1038/nature08460
Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10(6):594-601. doi:10.1038/nm1052
Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500-4. doi:10.1038/nature11183
Lamming DW, Sabatini DM. A Central role for mTOR in lipid homeostasis. Cell Metab. 2013;18(4):465-9. doi:10.1016/j.cmet.2013.08.002